ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EXAS EXACT Sciences Corporation

52.55
-0.98 (-1.83%)
Last Updated: 18:02:12
Delayed by 15 minutes
Share Name Share Symbol Market Type
EXACT Sciences Corporation NASDAQ:EXAS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.98 -1.83% 52.55 52.50 52.61 53.94 51.73 53.91 512,303 18:02:12

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

03/02/2025 11:00am

Business Wire


EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart


From Jan 2025 to Feb 2025

Click Here for more EXACT Sciences Charts.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Fourth quarter 2024 webcast & conference call details

Date: 

 

Wednesday, February 19, 2025

Time: 

 

5 p.m. ET

Webcast: 

 

The live webcast can be accessed at www.exactsciences.com

Telephone: 

 

Domestic callers, dial 888-330-2384 

 

 

International callers, dial +1 240-789-2701

           

 

Access code for both domestic and international callers: 4437608

 A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Erik Holznecht Exact Sciences Corp. investorrelations@exactsciences.com 608-800-6605

1 Year EXACT Sciences Chart

1 Year EXACT Sciences Chart

1 Month EXACT Sciences Chart

1 Month EXACT Sciences Chart

Your Recent History

Delayed Upgrade Clock